Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buspirone effects on reward processing
NCT05357547Phase 2Completed
- Sponsor
- University of Oxford
- Start
- May 2022
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of buspirone in anhedonia ((none)), major depressive disorder (MDD), sponsored by University of Oxford. Started May 2022; status: completed.
02
Drugs
buspirone
03
Conditions
anhedonia ((none))major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05357547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05357547.